[{"address1": "5858 Horton Street", "address2": "Suite 170", "city": "EmeryVille", "state": "CA", "zip": "94608", "country": "United States", "phone": "510 318 9098", "website": "https://www.estrellabio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Cheng  Liu Ph.D.", "age": 56, "title": "CEO, President & Director", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Jiandong  Xu", "title": "Chief Financial Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.4, "open": 1.395, "dayLow": 1.35, "dayHigh": 1.46, "regularMarketPreviousClose": 1.4, "regularMarketOpen": 1.395, "regularMarketDayLow": 1.35, "regularMarketDayHigh": 1.46, "beta": 0.213, "volume": 26561, "regularMarketVolume": 26561, "averageVolume": 93612, "averageVolume10days": 24620, "averageDailyVolume10Day": 24620, "marketCap": 53109400, "fiftyTwoWeekLow": 0.81, "fiftyTwoWeekHigh": 33.0, "fiftyDayAverage": 1.25596, "twoHundredDayAverage": 1.193685, "currency": "USD", "enterpriseValue": 48386096, "floatShares": 10363242, "sharesOutstanding": 36376300, "sharesShort": 39985, "sharesShortPriorMonth": 17602, "sharesShortPreviousMonthDate": 1719532800, "dateShortInterest": 1722384000, "sharesPercentSharesOut": 0.0011, "heldPercentInsiders": 0.71033996, "heldPercentInstitutions": 0.00348, "shortRatio": 0.68, "impliedSharesOutstanding": 36376300, "bookValue": 0.233, "priceToBook": 6.2660947, "lastFiscalYearEnd": 1688083200, "nextFiscalYearEnd": 1719705600, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -6092163, "trailingEps": -0.27, "52WeekChange": -0.81795514, "SandP52WeekChange": 0.24822903, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "ESLA", "underlyingSymbol": "ESLA", "shortName": "Estrella Immunopharma, Inc.", "longName": "Estrella Immunopharma, Inc.", "firstTradeDateEpochUtc": 1631626200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "aa42da4c-674b-32a3-bdaa-7ca46edb3082", "messageBoardId": "finmb_1802952199", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.46, "recommendationKey": "none", "totalCash": 4727290, "totalCashPerShare": 0.13, "totalDebt": 4000, "quickRatio": 34.134, "currentRatio": 62.339, "debtToEquity": 0.047, "returnOnAssets": -0.64896005, "returnOnEquity": -2.78121, "freeCashflow": -13261465, "operatingCashflow": -15820038, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-08-15"}]